SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for CorMedixs DefenCath could fall sharply in 2027 has fueled a steep selloff and concern about future pricing and sales. Traders dispute how conclusive DaVitas estimate is, pointing to CMSs finalized payment rate and arguing the outlook depends on quarterly calculations and DefenCath uptake.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA approval of Inovios competing RRP treatment has put Precigens PAPZIMEOS under scrutiny, with traders debating whether the new option will erode its market position. Some fear stronger competition, while others point to Precigens first-mover and full-approval advantages and question Inovios ability to commercialize its drug.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is drawing attention after Brazil approved its Valaris merger, which traders see as a step toward closing the deal, alongside recent offshore contract wins and higher day-rate expectations. Bulls anticipate improved scale and a potential short squeeze, while skeptics point to merger-related dilution, debt and the upcoming earnings report.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,942,077.7905448. The last known price of Zcash is 1,263.32437248 USD and is up 2.82 over the last 24 hours. It is currently trading on 668 active market(s) with $1,115,981,976.30 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp rebound and resilience amid broader crypto weakness and Binance hack fears have traders highlighting its privacy features and speculating about a safe-haven shift into ZEC; some also point to the upcoming NU7 upgrade. Others view the rally as overextended and expect further declines.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings beat, supported by Eylea HD and Sanofi collaboration growth, has driven a sharp share-price breakout to multiyear highs. Traders are broadly celebrating the results, while some are watching whether the rally can hold amid wider market weakness.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons quarterly results beat expectations, with record refinery utilization and strong refining performance drawing attention amid tight global diesel supplies linked to geopolitical disruptions. Traders largely welcomed the results and refining strength, though some questioned the stocks muted reaction and whether elevated oil and refining margins can last.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

FLY is drawing attention amid a sharp selloff that traders largely link to broader market and space-sector weakness, with many saying they see no new company-specific bad news. Some also worry about uncertainty around Alpha launch timing and want a firm update, while bullish traders view the drop as an opportunity.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels sharply weaker quarterly outlook, driven by soft PC demand and manufacturing constraints, triggered a steep selloff and analyst downgrades. Traders are split between calling the decline an overreaction and buying the dip, and warning that execution problems and continued weakness could bring further losses.

Coeur Mining, Inc. engages in the well-diversified, growing precious metals producer with a focus on generating sustainable, high-quality cash flow and returns from a balanced, prospective asset base in mining-friendly jurisdictions along with commitment to exploration and expansions. It operates through the following segments: Palmarejo, Rochester, Kensington, Wharf and Silvertip. The Palmarejo segment includes a gold-silver complex. The Rochester segment operates an open pit heap leach silver-gold mine in northwestern Nevada. The Kensington segment relates to an underground gold mine located north of Juneau, Alaska. The Wharf segment focuses on an open pit heap leach gold mine located near Lead, South Dakota. The Silvertip segment silver-zinc-lead exploration located in the state of Sonora in northern Mexico. The company was founded in 1928 and is headquartered in Chicago, IL.

Coeur Mining Inc

Coeur Mining is drawing attention after falling to a new 52-week low amid a sharp selloff in gold, silver and mining stocks; traders also point to put-heavy options activity. The discussion is split between dip-buyers and traders warning that weaker metal prices, higher costs and continued downside momentum could pressure miners further.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A rally to a fresh 52-week high ahead of an expected quarterly report has traders focused on BRIUMVI growth and whether results can justify the run; some expect an earnings-driven move, while others warn the stock may be priced for a beat. Buyout speculation and possible short covering are also fueling bullish chatter, but no deal is confirmed and the earnings timing remains uncertain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Pacer US Small Cap Cash Cows ETF (CALF) a Strong ETF Right Now?

Should Pacer US Small Cap Cash Cows ETF (CALF) Be on Your Investing Radar?

Macy’s Raises Full Year Outlook After Strong Q2 — Says Inventories ‘Well-Positioned’ Heading Into Second Half Of 2026

Equity

Macy’s raised its fiscal 2026 outlook after comparable sales grew across all three nameplates, led by record second-quarter sales volume at Bloomingdale’s.

MBLY Stock On Track For Best Single-Day Gains In Over A Year – CEO Highlights Stronger-Than-Expected Start To 2026

Mobileye CEO Amnon Shashua said the company was off to a stronger-than-expected start in 2026.

Pacer Funds Trust - Pacer US Small Cap Cash Cows ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Company-wide comparable sales rose 2.7% year on year, marking the fifth consecutive quarter of growth.</li><li>Macy’s raised its FY26 sales, comparable-sales, EBITDA margin and EPS guidance.</li><li>Net sales increased 1.1% to $4.9 billion, while adjusted diluted earnings per share came in at $0.63.&nbsp;</li></ul><p>Macy’s Inc. (M) reported stronger-than-expected fiscal second-quarter results on Thursday and raised its full-year outlook as comparable sales remained positive across Macy’s, Bloomingdale’s and Bluemercury.</p><p>Net sales increased 1.1% to $4.9 billion, while adjusted diluted earnings per share (EPS) came in at $0.63. Fiscal.ai consensus estimates showed roughly $4.81 billion in net sales and $0.37 in adjusted EPS, implying beats of about 1.2% and 70%, respectively.</p><p>The EPS figure included a $0.23 net tariff refund benefit. Excluding that benefit, adjusted EPS was $0.40, still above the Fiscal.ai estimate.</p><h2 class="st-heading-2">Record Q2 Sales For Bloomingdale's</h2><p>Macy’s comparable sales rose 1.1%, including 1.9% growth at Reimagine 200 locations. However, Bloomingdale’s was the standout, with comparable sales rising 11.3% and reaching the highest second-quarter sales volume in the brand’s history. Bluemercury comparable sales increased 6.2%.</p><p>The company-wide comparable sales rose 2.7% year on year, marking the fifth consecutive quarter of growth.</p><p>CEO Tony Spring said the results reflected continued progress under Macy’s Bold New Chapter strategy, including the performance of Reimagine 200 locations and growth at its luxury nameplates.</p><h2 class="st-heading-2">Inventories ‘Well-Positioned’ Heading Into Second Half of 2026</h2><p>Merchandise inventories increased 2.5% year over year, but Macy’s said both their composition and level are “well-positioned” heading into the second half of 2026.&nbsp;</p><p>The company's gross margin expanded 180 basis points to 41.5%. Excluding the tariff-refund benefit and accounting for ongoing tariff and fuel costs, gross margin was up 10 basis points.</p><h2 class="st-heading-2">Macy’s Raises FY26 Guidance</h2><p>Macy’s lifted its FY26 net sales forecast to $21.675 billion to $21.825 billion from $21.5 billion to $21.75 billion. Comparable sales are now expected to rise 1.0% to 1.5%, up from 0.5% to 1.2%.</p><p>Adjusted EPS guidance has also been increased from $2.00 to $2.20 to $2.15 to $2.35, while adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) margin guidance rose to 7.8% to 8.0% from 7.7% to 7.9% earlier.</p><h2 class="st-heading-2">What Retail Investors Think About Macy's Stock?</h2><p>Retail sentiment for Macy’s on Stocktwits turned ‘bullish’ from ‘neutral’ amid 'high' message volume.&nbsp;</p><figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_09_10_164345_bfcb3e8564.png" alt="Screenshot 2026-09-10 164345.png" width="827" height="470"><figcaption>M stock retail sentiment on September 10 as of 7:30 a.m. ET | Source: Stocktwits</figcaption></figure><p>Macy's (M) stock was trading down about 3% in Thursday's premarket at the time of this writing. The stock has fallen 5.4% so far this year but is up 26% in the last 12 months.</p><p><strong>See Also:&nbsp;</strong><a href="https://stocktwits.com/news-articles/markets/equity/uber-weride-spain-robotaxi-permit-tesla-cybercab-av/cZtaIzbRJCn"><strong>Uber’s Robotaxi Ambitions Gain Momentum With Spain Permit As Tesla’s Cybercab Launch Raises AV Stakes</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

A smartphone displays the logo of Macy's Inc. (Photo illustration by Cheng Xin/Getty Images)

Macy’s Inc. (M) reported stronger-than-expected fiscal second-quarter results on Thursday and raised its full-year outlook as comparable sales remained positive across Macy’s, Bloomingdale’s and Bluemercury.

American Century ETF Trust - Avantis U.S. Small Cap Value ETF

Pacer Funds Trust - Pacer US Small Cap Cash Cows 100 ETF

Macy's Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$58.50
Prev Close	$58.38
Open	$58.23
Dividend Yield	N/A
50-Day Moving Average	$56.12
Beta	N/A
Avg. Volume	641,757.42
PE Ratio	N/A

52-Week High	$58.67
52-Week Low	$41.94
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

CALF Fundamentals